GLP-1 Medication and Breast Cancer: History, Risk, and the Evidence

The baseline risk this sits on top of

Before getting to the medication, the underlying relationship matters: obesity is one of the more consistently established risk factors for postmenopausal breast cancer, and it is also associated with worse outcomes after diagnosis¹. The Women's Health Initiative — one of the largest long-running cohorts in women's health — found breast cancer incidence and mortality both tracked with metabolic syndrome and obesity status². The relationship is more nuanced before menopause: a 2023 meta-analysis found the obesity–breast cancer link differs by menstrual status, with the association strongest and most consistent after menopause and considerably murkier before it³. That distinction matters because it means "does losing weight lower my breast cancer risk" doesn't have one universal answer — it depends heavily on where you are in the menopause transition, which is the same distinction our perimenopause and menopause guide walks through for other outcomes.

What the newest data on GLP-1s and cancer risk shows

The obesity-cancer link is well established; whether treating obesity with a GLP-1 specifically changes cancer risk is a newer and still-developing question. A 2025 JAMA Oncology study looking at cancer risk in adults with obesity treated with GLP-1 receptor agonists is among the first large analyses aimed directly at this question⁴, and a 2025 meta-analysis of randomized controlled trials examining cancer outcomes across the drug class found no signal of increased cancer risk overall⁶. Neither of these is a breast-cancer-specific answer, but they are the closest things to a population-level baseline currently available.

What the data in breast cancer survivors actually shows

The most directly relevant study is a 2026 retrospective cohort from MD Anderson, the largest description to date of real-world GLP-1 use in breast cancer survivors. Among just over 1,000 patients with non-metastatic breast cancer who received a GLP-1 medication, semaglutide and tirzepatide users lost a modest amount of weight (roughly 2-3% at three to twelve months — less dramatic than the general-population obesity trials), and GLP-1 use was not associated with a difference in disease-free survival. It was associated with meaningfully better overall survival compared with non-users (hazard ratio 0.37), though the authors were explicit that this is a real-world, non-randomized comparison that cannot establish cause and effect, and called for actual clinical trials in this population⁵. A separate 2026 study looking at cardiovascular outcomes specifically in women with type 2 diabetes and a breast cancer history found real-world GLP-1 use associated with favorable cardiovascular patterns in that group as well⁷. Read together, this is genuinely reassuring early evidence — and it is exactly that: early, observational, and not yet the kind of trial evidence that lets a clinician say "this is proven safe and beneficial" rather than "the early signal is good."

The question this article won't answer for you

One question that comes up often — whether a GLP-1's effect on gastric emptying meaningfully changes the absorption of tamoxifen or other oral hormonal therapies — does not currently have a dedicated pharmacokinetic study behind it that we could verify. That is worth saying plainly rather than guessing: this is a reasonable, specific question to bring to an oncologist directly, and the honest answer today is that the targeted research doesn't yet exist to settle it either way.

Did the 2025 hormone therapy label change affect breast cancer survivors?

Not in the way the headlines suggested. On November 10, 2025, the FDA asked makers of menopausal hormone therapy to take the breast cancer statement, along with the heart disease and dementia statements, out of the boxed warning at the top of the label, and on February 12, 2026 it approved the first six updated labels⁸⁹. For systemic products, the FDA kept the breast cancer warning in the body of the label⁸, and ACOG still says systemic hormone therapy is usually not recommended for women who have ever had breast cancer, with nonhormonal treatments tried first after hormone-sensitive breast cancer¹⁰. Our guide to whether HRT causes weight gain sets out exactly what moved.

What this means in practice

If you are a breast cancer survivor or currently in treatment and considering a GLP-1, this is a three-way conversation — your oncologist, your prescribing clinician, and you — not a decision to make from a label or a single retrospective study. Bring your full treatment history, including any hormonal therapy, and ask specifically whether your care team has seen the 2026 survivor data. This is exactly the kind of history our guide to choosing a GLP-1 provider says should shape which program you pick — a provider who asks about oncology history at intake, rather than one that only asks about your weight goal, is doing the job. This guide is educational only and not medical advice.